News

Endpoints News17m
Dai­ichi Sankyo says pro­duc­tion boost in US will help cush­ion tar­iff im­pact
Daiichi Sankyo reaffirms US manufacturing expansion, including for Enhertu, will help with Trump's proposed tariffs. $350M ...
Endpoints News1h
Boehringer’s up­dat­ed re­sults in HER2-mu­tat­ed lung can­cer im­press
Boehringer Ingelheim's zongertinib shows promising results in lung cancer trial with 71% response rate and 14-month median ...
Endpoints News3h
Eu­ro­pean reg­u­la­tors rec­om­mend new drugs from Ver­tex, Am­gen and Jazz
Vertex Pharmaceuticals, Amgen and Jazz Pharmaceuticals are among companies that received a positive opinion from European ...
Endpoints News4h
GSK’s check­point block­er Jem­per­li cures bio­mark­er-dri­ven rec­tal can­cer
GSK's Jemperli shows 100% efficacy in 49 MMRd rectal cancer patients, with complete disease elimination after six months' ...
Endpoints News5h
Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?
Globally, approximately 300 million people are grappling with obesity, a complex disease that has a profound impact on a ...
Endpoints News7h
Keytru­da around head and neck can­cer surgery cuts chance of dis­ease com­ing back
Merck's Keytruda shows 27% reduced risk of recurrence/death in head & neck cancer when used before & after surgery, with FDA ...
Endpoints News7h
Rev­o­lu­tion Med­i­cine’s KRAS drug shows po­ten­tial in ear­ly cut of lung can­cer da­ta
Revolution Medicines' zoldonrasib shows 61% response rate in lung cancer patients with KRAS G12D mutations in Phase 1 trial, ...
Endpoints News2h
Mer­ck KGaA to buy rare can­cer biotech Spring­Works for $3.9B
Merck KGaA said Monday it has inked a “definitive agreement” to acquire Pfizer spinout SpringWorks Therapeutics for an equity value of around $3.9 billion, rounding off several months of negotiations.